Agios Pharmaceuticals, INC Form 4 insider transactions

Agios Pharmaceuticals Director Cynthia Smith converted 2,302 restricted stock units into common stock on August 11, 2025, increasing her direct beneficial ownership to 12,414 shares.

Agios Pharmaceuticals CEO Brian Goff sold 11,085 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Agios Pharmaceuticals Director David Scadden exercised stock options and simultaneously sold an equal number of common shares on July 10, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Agios Pharmaceuticals' Chief Medical Officer, Sarah Gheuens, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Agios Pharmaceuticals, Inc. Director Jay T. Backstrom was granted 23,393 stock options and 4,341 restricted stock units, effective July 8, 2025, as part of an equity incentive.

Agios Pharmaceuticals' Chief Medical Officer, Sarah Gheuens, reported the acquisition of common stock through restricted stock unit vesting and a subsequent sale to cover tax obligations, as part of a pre-arranged 10b5-1 plan.

Agios Pharmaceuticals' Chief Legal Officer, James William Burns, reported the vesting of 6,000 performance share units and the subsequent sale of 2,799 shares to cover tax obligations, as detailed in a recent SEC Form 4 filing.

Agios Pharmaceuticals' Chief Medical Officer, Sarah Gheuens, reported the vesting of 6,000 performance share units and the subsequent sale of 2,909 shares to cover tax obligations, as detailed in a recent SEC Form 4 filing.

Agios Pharmaceuticals' Chief Financial Officer, Cecilia Jones, reported the acquisition of 6,000 common stock shares from performance share unit vesting and the subsequent sale of 1,780 shares to cover tax obligations, as disclosed in a recent SEC Form 4 filing.

Agios Pharmaceuticals' Chief Commercial Officer, Tsveta Milanova, acquired 6,000 common shares through the vesting of performance share units and subsequently sold 2,770 shares to cover tax withholding obligations, as disclosed in a recent SEC Form 4 filing.

Agios Pharmaceuticals CEO Brian Goff reported the acquisition of common stock through performance share unit vesting and subsequent sales to cover tax obligations, executed under pre-arranged Rule 10b5-1 plans.

Agios Pharmaceuticals Director Rahul Ballal reported the acquisition of new restricted stock units and stock options, alongside the conversion of previously granted restricted stock units into common stock.

Agios Pharmaceuticals, Inc. Director Jeffrey D. Capello reported the acquisition of 2,120 common shares from RSU vesting and new grants of 2,861 restricted stock units and 15,768 stock options.

Agios Pharmaceuticals, Inc. Director Kaye Foster-Cheek reported the vesting of 2,120 restricted stock units into common stock and the grant of 2,816 new restricted stock units and 15,768 stock options.

Agios Pharmaceuticals Director Jacqualyn Fouse has reported the conversion of 2,120 restricted stock units into common stock and received new grants of 2,816 restricted stock units and 15,768 stock options.

Agios Pharmaceuticals, Inc. Director Maykin Ho reported the acquisition of 2,816 restricted stock units and 15,768 stock options, alongside the conversion of 2,120 restricted stock units into common stock.

Agios Pharmaceuticals, Inc. Director Catherine Owen reported the acquisition of 2,120 common shares from vested restricted stock units, alongside new grants of 2,816 restricted stock units and 15,768 stock options.

Agios Pharmaceuticals, Inc. Director David Scadden has reported the acquisition of common stock, restricted stock units, and stock options through grants and vesting events, increasing his beneficial ownership in the company.

Agios Pharmaceuticals, Inc. Director Cynthia Smith reported the vesting of previously granted restricted stock units and the acquisition of new equity awards, including restricted stock units and stock options.

Jeffrey D. Capello, a Director at Agios Pharmaceuticals, Inc., converted 1,977 restricted stock units into common stock on June 13, 2025, as part of a routine vesting schedule.

Agios Pharmaceuticals, Inc. Director Catherine Owen reported the vesting and acquisition of 1,977 shares of common stock through the exercise of restricted stock units on June 13, 2025, increasing her direct beneficial ownership to 3,953 shares.

Director Jacqualyn Fouse reports acquisition of shares through restricted stock unit vesting and subsequent sale to cover tax obligations.

Krishnan Viswanadhan, Chief Corp Dev & Strategy at Agios Pharmaceuticals, acquired stock options and restricted stock units on March 5, 2025.

James William Burns, Chief Legal Officer of Agios Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units.

Cecilia Jones, CFO of Agios Pharmaceuticals, reports acquisition and disposal of common stock and derivative securities, including restricted stock units and stock options, primarily related to vesting and tax obligations.

Tsveta Milanova, Chief Commercial Officer of Agios Pharmaceuticals, reports the acquisition and disposal of common stock and derivative securities, including restricted stock units and stock options, as per a pre-arranged trading plan.

Brian Goff, CEO of Agios Pharmaceuticals, reports acquisition and disposal of common stock and derivative securities, including restricted stock units and stock options, primarily related to vesting and tax obligations.

Sarah Gheuens, Chief Medical Officer of Agios Pharmaceuticals, reports acquisition and disposal of common stock and derivative securities, including transactions to cover tax obligations related to vesting restricted stock units.

Theodore James Jr. Washburn, Principal Accounting Officer of Agios Pharmaceuticals, reports acquisition and disposal of common stock and restricted stock units.

Theodore James Jr. Washburn, Principal Accounting Officer of Agios Pharmaceuticals, sold shares to cover tax obligations related to vesting restricted stock units.